Brilliant blue g
Tissueblue (brilliant blue g) is a small molecule pharmaceutical. Brilliant blue g was first approved as Tissueblue on 2019-12-20. It is known to target P2X purinoceptor 7.
Download report
Favorite
FDA Novel Drug Approvals 2019
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Tissueblue
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Brilliant blue g
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TISSUEBLUE | DORC Dutch Ophthalmic Research Center | N-209569 RX | 2019-12-20 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tissueblue | New Drug Application | 2020-12-18 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BRILLIANT BLUE G, TISSUEBLUE, DUTCH OPHTHALMIC | |||
| 2026-12-20 | ODE-282 | ||
| 2024-12-20 | NCE | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal perforations | D012167 | EFO_1001028 | — | — | 1 | — | 1 | 2 | |
| Epiretinal membrane | D019773 | HP_0100014 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Proliferative vitreoretinopathy | D018630 | EFO_1001129 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BRILLIANT BLUE G |
| INN | — |
| Description | Tissueblue (brilliant blue g) is a small molecule pharmaceutical. Brilliant blue g was first approved as Tissueblue on 2019-12-20. It is known to target P2X purinoceptor 7. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCOc1ccc(Nc2ccc(/C(=C3/C=C/C(=[N+](/CC)Cc4cccc(S(=O)(=O)[O-])c4)C=C3C)c3ccc(N(CC)Cc4cccc(S(=O)(=O)[O-])c4)cc3C)cc2)cc1.[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 6104-59-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4173394 |
| ChEBI ID | — |
| PubChem CID | 61365 |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
P2RX7
P2RX7
Organism
Homo sapiens
Gene name
P2RX7
Gene synonyms
NCBI Gene ID
Protein name
P2X purinoceptor 7
Protein synonyms
ATP receptor, P2X7 receptor, P2Z receptor, Purinergic receptor, purinergic receptor P2X, ligand gated ion channel, 7, purnergic receptor P2X 7
Uniprot ID
Mouse ortholog
P2rx7 (18439)
P2X purinoceptor 7 (Q9Z1M0)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,658 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
128 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more